Evidence map›Paper›PMID 37051527›Full record

ArticleFrontiers in oncology2023

Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging.

Dannel Yeo, Steven Kao, Ruta Gupta, Sara Wahlroos, Althea Bastian, Heidi Strauss, Vera Klemm, Prajwol Shrestha, Arturo B Ramirez, Lillian Costandy and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Dannel YeoLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW, Australia.
Steven KaoFaculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Ruta GuptaFaculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Sara WahlroosMedical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
Althea BastianLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW, Australia.
Heidi StraussLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW, Australia.
Vera KlemmLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW, Australia.
Prajwol ShresthaLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW, Australia.
Arturo B RamirezRareCyte Inc., Seattle, WA, United States.
Lillian CostandyRareCyte Inc., Seattle, WA, United States.
Ryan HustonRareCyte Inc., Seattle, WA, United States.
Brady S GardnerRareCyte Inc., Seattle, WA, United States.
Peter GrimisonFaculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Jonathan R ClarkFaculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
John E J RaskoLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW, Australia.
Sydney Local Health District · AUUniversity of Sydney · AUCentenary Institute · AUChris O’Brien Lifehouse · AURoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The reliable and accurate detection of rare circulating tumor cells (CTCs) from cancer patient blood samples promises advantages in both research and clinical applications. Numerous CTC detection methods have been explored that rely on either the physical properties of CTCs such as density, size, charge, and/or their antigen expression profiles. Multiple factors can influence CTC recovery including blood processing method and time to processing. This study aimed to examine the accuracy and sensitivity of an enrichment-free method of isolating leukocytes (AccuCyte Method: Healthy human blood samples, spiked with cancer cells from cancer cell lines, as well as blood samples obtained from 4 subjects diagnosed with cancer (2 pancreatic, 1 thyroid, and 1 small cell lung) were processed using the AccuCyte-CyteFinder system to assess recovery rate, accuracy, and reliability over a range of processing times. Results: The AccuCyte-CyteFinder system was highly accurate (95.0%) at identifying cancer cells in spiked-in samples (in 7.5 mL of blood), even at low spiked-in numbers of 5 cells with high sensitivity (90%). The AccuCyte-CyteFinder recovery rate (90.9%) was significantly higher compared to recovery rates obtained by density gradient centrifugation (20.0%) and red blood cell lysis (52.0%). Reliable and comparable recovery was observed in spiked-in samples and in clinical blood samples processed up to 72 hours post-collection. Reviewer analysis of images from spiked-in and clinical samples resulted in high concordance (R-squared value of 0.998 and 0.984 respectively). Discussion: The AccuCyte-CyteFinder system is as an accurate, sensitive, and clinically practical method to detect and enumerate cancer cells. This system addresses some of the practical logistical challenges in incorporating CTCs as part of routine clinical care. This could facilitate the clinical use of CTCs in guiding precision, personalized medicine.

Indexed as

biomarkerscancerliquid biopsymetastasisprecision medicine

Identifiers

PMID37051527
PMCPMC10083432
OpenAlexW4360982810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.